Citations to this article
Citation Information: JCI Insight. 2017;2(13):e92264. https://doi.org/10.1172/jci.insight.92264.
Abstract
Nonalcoholic fatty liver disease prevalence is soaring with the obesity pandemic, but the pathogenic mechanisms leading to the progression toward active nonalcoholic steatohepatitis (NASH) and fibrosis, major causes of liver-related death, are poorly defined. To identify key components during the progression toward NASH and fibrosis, we investigated the liver transcriptome in a human cohort of NASH patients. The transition from histologically proven fatty liver to NASH and fibrosis was characterized by gene expression patterns that successively reflected altered functions in metabolism, inflammation, and epithelial-mesenchymal transition. A meta-analysis combining our and public human transcriptomic datasets with murine models of NASH and fibrosis defined a molecular signature characterizing NASH and fibrosis and evidencing abnormal inflammation and extracellular matrix (ECM) homeostasis. Dermatopontin expression was found increased in fibrosis, and reversal of fibrosis after gastric bypass correlated with decreased dermatopontin expression. Functional studies in mice identified an active role for dermatopontin in collagen deposition and fibrosis. PPARα activation lowered dermatopontin expression through a transrepressive mechanism affecting the Klf6/TGFβ1 pathway. Liver fibrotic histological damages are thus characterized by the deregulated expression of a restricted set of inflammation- and ECM-related genes. Among them, dermatopontin may be a valuable target to reverse the hepatic fibrotic process.
Authors
Philippe Lefebvre, Fanny Lalloyer, Eric Baugé, Michal Pawlak, Céline Gheeraert, Hélène Dehondt, Jonathan Vanhoutte, Eloise Woitrain, Nathalie Hennuyer, Claire Mazuy, Marie Bobowski-Gérard, Francesco Paolo Zummo, Bruno Derudas, Ann Driessen, Guy Hubens, Luisa Vonghia, Wilhelmus J. Kwanten, Peter Michielsen, Thomas Vanwolleghem, Jérôme Eeckhoute, An Verrijken, Luc Van Gaal, Sven Francque, Bart Staels
Total citations by year
Citations to this article in year 2023 (13)
| Title and authors | Publication | Year |
|---|---|---|
|
DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP
Ye D, Wang Y, Deng X, Zhou X, Liu D, Zhou B, Zheng W, Wang X, Fang L |
Cell Death and Disease | 2023 |
|
Identification of Key Target Genes and Pathway Analysis in Nonalcoholic Fatty Liver Disease Via Integrated Bioinformatics Analysis
Chen X, Zhang L, Wang Y, Li R, Yang M, Gao L |
2023 | |
|
EMP1 as a Potential Biomarker in Liver Fibrosis: A Bioinformatics Analysis
Chen X, Lv X, Han M, Hu Y, Zheng W, Xue H, Li Z, Li K, Tan W |
Gastroenterology Research and Practice | 2023 |
|
Identification of disease-related genes and construction of a gene co-expression database in non-alcoholic fatty liver disease
Ye H, Sun M, Su M, Chen D, Liu H, Ma Y, Luo W, Li H, Xu F |
Frontiers in Genetics | 2023 |
|
Dysregulated peripheral proteome reveals NASH-specific signatures identifying patient subgroups with distinct liver biology
Stiglund N, Hagström H, Stål P, Cornillet M, Björkström NK |
Frontiers in immunology | 2023 |
|
Reciprocal Regulation of Hepatic TGF-β1 and Foxo1 Controls Gluconeogenesis and Energy Expenditure
Pan Q, Ai W, Chen Y, Kim DM, Shen Z, Yang W, Jiang W, Sun Y, Safe S, Guo S |
Diabetes | 2023 |
|
TRAF2 decreases lipid accumulation in hepatocytes under endoplasmic reticulum stress: TRAF2 increases the ubiquitination of XBP1s
Li S, Li Y, Wang X, Xia Z, Hu R |
Acta Biochimica et Biophysica Sinica | 2023 |
|
GARP on hepatic stellate cells is essential for the development of liver fibrosis
Zhang X, Sharma P, Maschmeyer P, Hu Y, Lou M, Kim J, Fujii H, Unutmaz D, Schwabe RF, Winau F |
Journal of Hepatology | 2023 |
|
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells
Kasahara N, Imi Y, Amano R, Shinohara M, Okada K, Hosokawa Y, Imamori M, Tomimoto C, Kunisawa J, Kishino S, Ogawa J, Ogawa W, Hosooka T |
Scientific Reports | 2023 |
|
Found in Translation – Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Wang S, Friedman SL |
Science Translational Medicine | 2023 |
|
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH
Cano L, Desquilles L, Ghukasyan G, Angenard G, Landreau C, Corlu A, Clément B, Turlin B, Le Ferrec E, Aninat C, Massart J, Musso O |
2023 | |
|
Chronic metabolic stress drives developmental programs and loss of tissue functions in non-transformed liver that mirror tumor states and stratify survival
Tzouanas CN, Sherman MS, Shay JE, Rubin AJ, Mead BE, Dao TT, Butzlaff T, Mana MD, Kolb KE, Walesky C, Pepe-Mooney BJ, Smith CJ, Prakadan SM, Ramseier ML, Tong EY, Joung J, Chi F, McMahon-Skates T, Winston CL, Jeong WJ, Aney KJ, Chen E, Nissim S, Zhang F, Deshpande V, Lauer GM, Yilmaz ÖH, Goessling W, Shalek AK |
2023 | |
|
Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD
Johanns M, Haas JT, Raverdy V, Vandel J, Chevalier-Dubois J, Guille L, Derudas B, Legendre B, Caiazzo R, Verkindt H, Gnemmi V, Leteurtre E, Derhourhi M, Bonnefond A, Froguel P, Eeckhoute J, Lassailly G, Mathurin P, Pattou F, Staels B, Lefebvre P |
2023 |
